These two get compared constantly because they belong to the same family and were developed to do the same job. If you've been reading peptide forums, you've probably seen ipamorelin described as the "clean" choice and GHRP-6 as the older, stronger, messier one. That reputation is mostly fair, and it comes down to a single concept: how selective each molecule is about what it switches on.
What ipamorelin and GHRP-6 have in common
Both are growth hormone secretagogues, sometimes called ghrelin mimetics. Ghrelin is the hormone best known for signaling hunger, but it also has a powerful side job: it tells your pituitary gland to release growth hormone. Ipamorelin and GHRP-6 both imitate ghrelin at that receptor, prompting a pulse of growth hormone. Because they work through a different doorway than the GHRH peptides like sermorelin, they're frequently paired with one for a larger combined release. They also both belong to the family that earned the GHRP label, which stands for growth hormone releasing peptide, a name that predates ipamorelin and is sometimes used loosely to cover the whole group.
How ipamorelin works
Ipamorelin binds to the ghrelin receptor and triggers growth hormone release, but it was specifically designed to do only that and nothing else. It is highly selective, meaning it activates the growth hormone pathway without meaningfully touching the other hormones that ghrelin-type molecules can stir up. In practice, that means it generally doesn't cause a strong hunger surge, and it tends to leave cortisol (a stress hormone) and prolactin (a hormone that can cause unwanted effects when elevated) largely alone. This clean profile is the entire reason it became popular.
How GHRP-6 works
GHRP-6 binds to the same ghrelin receptor and produces a strong growth hormone release, often a robust one. The catch is that it isn't selective. Because it activates the ghrelin pathway more broadly, GHRP-6 typically produces a pronounced increase in hunger, sometimes a dramatic one, within minutes of injection. At higher doses it can also nudge cortisol and prolactin upward. None of that makes it a bad molecule; the strong hunger response is even useful in certain research contexts. It simply means GHRP-6 comes with effects you will notice.
Key differences
Selectivity is the whole story. Ipamorelin is the scalpel: it raises growth hormone and stops there. GHRP-6 is the broad lever: it raises growth hormone effectively but pulls on neighboring systems at the same time. For most people exploring growth hormone support for sleep, recovery, or age-related decline, the neighboring effects of GHRP-6 are unwanted noise.
The most noticeable practical difference is appetite. GHRP-6's hunger signal is immediate and strong, which can be disruptive if your goal has anything to do with body composition or simply not wanting to feel ravenous after a bedtime dose. Ipamorelin's lack of that signal is precisely why people reach for it instead.
The other practical difference is the cortisol and prolactin question. Elevated cortisol works against many of the recovery and sleep benefits people are pursuing in the first place, and elevated prolactin can produce its own unwanted effects. Ipamorelin's selectivity sidesteps both at typical research doses. GHRP-6 carries more of that risk, especially as the dose climbs. Both are sold as research compounds and are not approved for human use, and both share the gentler, feedback-respecting nature of all the secretagogues compared to injecting growth hormone directly.
Duration and dosing are similar enough that they don't drive the decision. Both are short-acting, clearing the body within a few hours, so both are typically taken on a timed schedule, often before sleep, to line up with the body's natural growth hormone rhythm. Neither one lingers the way a long-acting peptide such as CJC-1295 with DAC does. That means the choice between ipamorelin and GHRP-6 really does rest on the side effect profile rather than on convenience, which is unusual: most peptide comparisons involve a convenience trade-off, and this one mostly doesn't.
| Ipamorelin | GHRP-6 | |
|---|---|---|
| Mechanism | Ghrelin receptor (selective) | Ghrelin receptor (broad) |
| GH release | Solid, clean | Strong |
| Hunger effect | Minimal | Pronounced, fast |
| Cortisol / prolactin | Largely unaffected | Can rise at higher doses |
| Reputation | The clean option | The older heavy hitter |
| Best for | Side-effect-free GH support | Maximal release, hunger acceptable |
Bottom line
Ipamorelin is the better fit for almost anyone whose main goal is growth hormone support without collateral effects. If you want a clean pulse, no hunger surge, and minimal disturbance to cortisol and prolactin, it's the reason "clean" became its nickname. It's also the more forgiving option for someone newer to this category.
GHRP-6 makes more sense when a strong release is the priority and the hunger effect is either acceptable or actively wanted, which is a narrower situation. It's a capable, well-studied molecule with a long history, but its lack of selectivity means most people choosing a secretagogue today land on ipamorelin instead. The exception is research interest in ghrelin's appetite signaling itself, where GHRP-6's strong hunger response stops being a drawback and becomes the point.
Where to go from here
Secretagogues are often paired with a GHRH analog rather than used alone, and that pairing is explained in CJC-1295 vs. Sermorelin. If you're choosing your very first growth hormone peptide and want the secretagogue-versus-GHRH framing, Ipamorelin vs. Sermorelin covers that decision directly. For the bigger-picture choice between stimulating and replacing growth hormone, see HGH vs. GH Peptides. To compare vendor pricing, the Peptide Price Lab tool tracks per-milligram costs across the market.